These cancer therapeutic drug nominations (both the heterocyclic chromenes and the sulfur-integrating derivatives) are enabled to inhibit the overexpression of EGFR (epidermal growth factor receptor), which triggers the emergence of numerous tumor subtypes (notably colon, breast, and ovarian). Here, EGFR is linked to cancer.